ALK and NTRK1 fusion molecules and uses thereof
Novel ALK and NTRK1 fusion molecules and uses are disclosed.
1. A method of treating a subject having cancer, comprising:
identifying the subject as having a DCTN1-ALK fusion polypeptide or a nucleic acid molecule encoding a DCTN1-ALK fusion polypeptide in said subject; and
administering to the identified subject an effective amount of an anti-cancer agent that reduces or inhibits activity or expression of the DCTN1-ALK fusion polypeptide, thereby treating the cancer in the subject,
wherein the DCTN1-ALK fusion polypeptide comprises the amino acid sequence of SEQ ID NO:7 or a fragment thereof, or a sequence at least 85% identical thereto.
2. The method of claim 1 , wherein said anti-cancer agent is a kinase inhibitor.
3. The method of claim 1 , wherein the subject is identified as having the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide by a sequencing method.
4. The method of claim 1 , wherein said cancer is an inflammatory myofibroblastic tumor, a Spitz tumor, a melanoma, a colorectal cancer, a lung cancer, a pancreatic cancer, an esophageal-gastric cancer, a thyroid cancer, or an adenocarcinoma.
5. The method of claim 1 , wherein said cancer is a lung cancer, and said lung cancer is a small cell lung cancer (SCLC), a non-small cell lung cancer (NSCLC), an adenocarcinoma of the lung, a bronchogenic carcinoma, a squamous cell carcinoma (SCC), or a combination thereof.
6. The method of claim 1 , wherein the anti-cancer agent comprises:
LDK-378, PF-02341066, XL228, an ALK-specific inhibitor, TAE-684, PF02341066 (crizotinib), AF-802, ASP-3026, CEP-37440, CEP-28122, or AP26113; or
an inhibitor comprising an antisense molecule, a ribozyme, an RNAi molecule, or a triple helix molecule that hybridizes to the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide or a transcription regulatory region, thereby blocking or reducing mRNA expression of the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide.
7. The method of claim 2 , wherein the kinase inhibitor is administered in combination with a second therapeutic agent or a different therapeutic modality.
8. The method of claim 7 , wherein the second therapeutic agent is a cytotoxic agent or a cytostatic agent.
9. The method of claim 8 , wherein the cytotoxic agent comprises an antimicrotubule agent, a topoisomerase inhibitor, a taxane, an antimetabolite, a mitotic inhibitor, an alkylating agent, an intercalating agent, an agent capable of interfering with a signal transduction pathway, or an agent that promotes apoptosis.
10. The method of claim 7 , wherein the second therapeutic agent is an immunomodulatory agent.
11. The method of claim 10 , wherein the immunomodulatory agent comprises IL-1, IL-2, IL-4, IL-6, IL-12, interferon alpha, interferon gamma, an immune cell growth factor, or GM-CSF.
12. The method of claim 1 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of the nucleotide sequence of one or more of exons 1-26 of DCTN1 of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto, and the nucleotide sequence of one or more of exons 20-29 of ALK of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto.
13. The method of claim 1 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of at least the nucleotide sequence of exon 26 of DCTN1 of SEQ ID NO: 6, and at least the nucleotide sequence of exon 20 of ALK of SEQ ID NO: 6.
14. The method of claim 1 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises a break point comprising the nucleotide sequence of SEQ ID NO: 5 or a fragment thereof.
15. The method of claim 1 , wherein the DCTN1-ALK fusion polypeptide comprises amino acids 1062-1069 or 1116-1362 of the amino acid sequence of SEQ ID NO: 7.
16. A method of treating a subject having a cancer, comprising:
identifying the subject as having a nucleic acid molecule encoding a DCTN1-ALK fusion polypeptide in a tumor nucleic acid sample from said subject; and
administering to the identified subject an effective amount of a kinase inhibitor that reduces or inhibits ALK activity, thereby treating the cancer in the subject,
wherein the DCTN1-ALK fusion polypeptide comprises the amino acid sequence of SEQ ID NO:7 or a fragment thereof, or a sequence at least 85% identical thereto.
17. The method of claim 16 , wherein the subject is identified as having the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide by a sequencing method.
18. The method of claim 16 , wherein said cancer comprises an inflammatory myofibroblastic tumor, a Spitz tumor, a melanoma, a colorectal cancer, a lung cancer, a pancreatic cancer, an esophageal-gastric cancer, a thyroid cancer, or an adenocarcinoma.
19. The method of claim 16 , wherein said cancer is a lung cancer, and said lung cancer is a small cell lung cancer (SCLC), a non-small cell lung cancer (NSCLC), an adenocarcinoma of the lung, a bronchogenic carcinoma, a squamous cell carcinoma (SCC), or a combination thereof.
20. The method of claim 16 , wherein the kinase inhibitor comprises:
LDK-378, PF-02341066, XL228, an ALK-specific inhibitor, TAE-684, PF02341066 (crizotinib), AF-802, ASP-3026, CEP-37440, CEP-28122, or AP26113; or
an inhibitor comprising an antisense molecule, a ribozyme, an RNAi molecule, or a triple helix molecule that hybridizes to the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide, or a transcription regulatory region that blocks or reduces mRNA expression of the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide.
21. The method of claim 16 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of the nucleotide sequence of one or more of exons 1-26 of DCTN1 of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto, and the nucleotide sequence of one or more of exons 20-29 of ALK of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto.
22. The method of claim 16 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of at least the nucleotide sequence of exon 26 of DCTN1 of SEQ ID NO: 6, and at least the nucleotide sequence of exon 20 of ALK of SEQ ID NO: 6.
23. The method of claim 16 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises a break point comprising the nucleotide sequence of SEQ ID NO: 5 or a fragment thereof.
24. The method of claim 16 , wherein the DCTN1-ALK fusion polypeptide comprises amino acids 1062-1069 or 1116-1362 of the amino acid sequence of SEQ ID NO: 7.
25. A method of treating a subject having an inflammatory myofibroblastic tumor, comprising:
identifying the subject as having a DCTN1-ALK fusion polypeptide or a nucleic acid molecule encoding a DCTN1-ALK fusion polypeptide in said subject;
administering to the identified subject an effective amount of LDK-378, thereby treating the inflammatory myofibroblastic tumor in the subject,
wherein the DCTN1-ALK fusion polypeptide comprises the amino acid sequence of SEQ ID NO: 7 or a fragment thereof, or an amino acid sequence at least 85% identical thereto.
26. The method of claim 25 , wherein the subject is identified as having the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide by a sequencing method.
27. The method of claim 25 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of the nucleotide sequence of one or more of exons 1-26 of DCTN1 of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto, and the nucleotide sequence of one or more of exons 20-29 of ALK of SEQ ID NO: 6 or a fragment thereof, or a nucleotide sequence at least 85% identical thereto.
28. The method of claim 25 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises an in-frame fusion of at least the nucleotide sequence of exon 26 of DCTN1 of SEQ ID NO: 6, and at least the nucleotide sequence of exon 20 of ALK of SEQ ID NO: 6.
29. The method of claim 25 , wherein the nucleic acid molecule encoding the DCTN1-ALK fusion polypeptide comprises a break point comprising the nucleotide sequence of SEQ ID NO: 5 or a fragment thereof.
30. The method of claim 25 , wherein the DCTN1-ALK fusion polypeptide comprises amino acids 1062-1069 or 1116-1362 of the amino acid sequence of SEQ ID NO: 7.